Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Faraz Bishehsari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5644-2586; OpenAlex author ID A5031237657; NIH RePORTER profile ID 11204459. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 9)
Trials
0
Grants
4
Labs led
2
Collaborators
14
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: none · 2024: 2 papers, 1 grant · 2025: 1 paper, 2 grants · 2026: 1 paper, 1 grant

Papers 11

  1. A Patient-Derived Organ-on-Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer. Last author DOI 10.1002/advs.202508934↗
  2. Stromal fibrin shapes immune infiltration landscape of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biomaterials.2025.123280↗
  3. Circadian transcriptome of pancreatic adenocarcinoma unravels chronotherapeutic targets. Last author DOI 10.1172/jci.insight.177697↗
  4. Cell Membrane Fatty Acids and PIPs Modulate the Etiology of Pancreatic Cancer by Regulating AKT. Co-author DOI 10.3390/nu17010150↗
  5. Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression. Last author DOI 10.1007/s11010-022-04377-5↗
  6. Correction to: Novel role of the Mu‑opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression. Last author DOI 10.1007/s11010-022-04400-9↗
  7. Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment. Last author DOI 10.1038/s41378-022-00370-6↗
  8. Opioid use as a potential risk factor for pancreatic cancer in the United States: An analysis of state and national level databases. Last author DOI 10.1371/journal.pone.0244285↗
  9. Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/biomedicines9070705↗
  10. Organ-Chip Models: Opportunities for Precision Medicine in Pancreatic Cancer. Last author DOI 10.3390/cancers13174487↗
  11. Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1159/000507457↗

Grants 4

  1. Fibrin-laden tumor stroma as a novel immunomodulatory factor in pancreatic ductal adenocarcinoma R01CA304572↗
  2. Development of a precision medicine platform for circadian based therapeutics in pancreatic cancer R01CA279487↗
  3. Discovery of Chronotherapeutic Candidate Targets in Pancreatic Cancer R03OD039982↗
  4. Personalized Organoid-Chip Model For Drug Testing in Pancreatic Cancer R21CA277110↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul J. Grippo · 2 shared papers, 1 shared grant, 2024–2026 · strength 1.38
  2. Taslim Ahmed Al-Hilal · 2 shared papers, 1 shared grant, 2021–2026 · strength 1.38
  3. Muhammad R. Haque · 5 shared papers, 2021–2022 · strength 0.88
  4. Usman Barlass · 5 shared papers, 2020–2022 · strength 0.85
  5. Andrew Armstrong · 3 shared papers, 2021–2022 · strength 0.54
  6. Darbaz Adnan · 2 shared papers, 2024–2026 · strength 0.53
  7. Deepak Sharma · 1 shared paper, 2024 · strength 0.26
  8. Mazharul Karim · 1 shared paper, 2025 · strength 0.22
  9. Megha Singhal · 1 shared paper, 2024 · strength 0.16
  10. Georgina E. Mancinelli · 1 shared paper, 2024 · strength 0.16
  11. Carolina Torres · 1 shared paper, 2024 · strength 0.16
  12. Giulia Orsi · 1 shared paper, 2024 · strength 0.16
  13. Ajaypal Singh · 1 shared paper, 2021 · strength 0.13
  14. Vishal Desai · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.